Q-omics provides the consensus-scored GTPBP6 profile across patient tissues and cancer cell-line models. GTPBP6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GTPBP6 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, GTPBP6 RNA expression shows 17,484 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KICH, and ACC as cancer lineages where GTPBP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTPBP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTPBP6 survival associations across molecular data types. GTPBP6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTPBP6 RNA expression–survival associations across cancer types. High GTPBP6 expression shows unfavorable associations in LIHC and KIRP, but favorable associations in UVM, PAAD, SKCM and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GTPBP6 RNA expression.
This table summarizes GTPBP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GTPBP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTPBP6 shows lower tumor expression in KICH, THCA and KIRP and higher tumor expression in LIHC, STAD and COAD. The KICH box plot shows higher GTPBP6 RNA expression in normal versus tumor tissue (log2 FC = −0.708, t-test p < 0.001).
This table shows molecular features associated with GTPBP6 in patient tissues and cancer cell lines. In patient samples, GTPBP6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GTPBP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
